<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Chin Med J (Engl)</journal-id><journal-id journal-id-type="iso-abbrev">Chin. Med. J</journal-id><journal-id journal-id-type="publisher-id">CMJ</journal-id><journal-title-group><journal-title>Chinese Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0366-6999</issn><publisher><publisher-name>Medknow Publications &amp; Media Pvt Ltd</publisher-name><publisher-loc>India</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29363651</article-id><article-id pub-id-type="pmc">5798057</article-id><article-id pub-id-type="publisher-id">CMJ-131-347</article-id><article-id pub-id-type="doi">10.4103/0366-6999.223849</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Rationale and Study Design for a Single-Arm Phase IIa Study Investigating Feasibility of Preventing Ischemic Cerebrovascular Events in High-Risk Patients with Acute Non-disabling Ischemic Cerebrovascular Events Using Remote Ischemic Conditioning</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shi-Meng</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Zhao</surname><given-names>Wen-Le</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Song</surname><given-names>Hai-Qing</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Ran</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Si-Jie</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ren</surname><given-names>Chang-Hong</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ovbiagele</surname><given-names>Bruce</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ji</surname><given-names>Xun-Ming</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1"></xref></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Wu-Wei</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China</aff><aff id="aff2"><label>2</label>Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC 29403, USA</aff><aff id="aff3"><label>3</label>Beijing Key Laboratory of Hypoxia Conditioning Translational Medicine, Beijing 100053, China</aff><aff id="aff4"><label>4</label>Department of Neurology, Medical University of South Carolina, Charleston, SC 29403, USA</aff><author-notes><corresp id="cor1"><bold>Address for correspondence:</bold> Dr. Xun-Ming Ji, Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing 100053, China E-Mail: <email xlink:href="jixm@ccmu.edu.cn">jixm@ccmu.edu.cn</email></corresp></author-notes><pub-date pub-type="ppub"><day>05</day><month>2</month><year>2018</year></pub-date><volume>131</volume><issue>3</issue><fpage>347</fpage><lpage>351</lpage><history><date date-type="received"><day>18</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>Copyright: © 2018 Chinese Medical Journal</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/3.0"><license-p>This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.</license-p></license></permissions><abstract><sec id="st1"><title><offsets xml_i="4437" xml_f="4448" txt_i="11" txt_f="22">Background:</offsets></title><p><offsets xml_i="4459" xml_f="5081" txt_i="23" txt_f="645">Acute minor ischemic stroke (AMIS) or transient ischemic attack (TIA) is a common cerebrovascular event with a considerable high recurrence. Prior research demonstrated the effectiveness of regular long-term remote ischemic conditioning (RIC) in secondary stroke prevention in patients with intracranial stenosis. We hypothesized that RIC can serve as an effective adjunctive therapy to pharmacotherapy in preventing ischemic events in patients with AMIS/TIA. This study aimed to investigate the feasibility, safety, and preliminary efficacy of daily RIC in inhibiting cerebrovascular/cardiovascular events after AMIS/TIA.</offsets></p></sec><sec id="st2"><title><offsets xml_i="5112" xml_f="5120" txt_i="647" txt_f="655">Methods:</offsets></title><p><offsets xml_i="5131" xml_f="5717" txt_i="656" txt_f="1242">This is a single-arm, open-label, multicenter Phase IIa futility study with a sample size of 165. Patients with AMIS/TIA receive RIC as an additional therapy to secondary stroke prevention regimen. RIC consists of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuffs on bilateral upper limbs twice a day for 90 days. The antiplatelet strategy is based on individual physician's best practice: aspirin alone, clopidogrel alone, or combination of aspirin and clopidogrel. We will assess the recurrence rate of ischemic stroke/TIA within 3 months as the primary outcomes.</offsets></p></sec><sec id="st3"><title><offsets xml_i="5748" xml_f="5760" txt_i="1244" txt_f="1256">Conclusions:</offsets></title><p><offsets xml_i="5771" xml_f="5949" txt_i="1257" txt_f="1435">The data gathered from the study will be used to determine whether a further large-scale, multicenter randomized controlled Phase II trial is warranted in patients with AMIS/TIA.</offsets></p></sec><sec id="st4"><title><offsets xml_i="5980" xml_f="5999" txt_i="1437" txt_f="1456">Trial Registration:</offsets></title><p><offsets xml_i="6010" xml_f="6043" txt_i="1457" txt_f="1490">ClinicalTrials.gov, NCT03004820; </offsets><ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT03004820"><offsets xml_i="6138" xml_f="6189" txt_i="1490" txt_f="1541">https://www.clinicaltrials.gov/ct2/show/NCT03004820</offsets></ext-link><offsets xml_i="6200" xml_f="6201" txt_i="1541" txt_f="1542">.</offsets></p></sec></abstract><kwd-group><kwd>Ischemic Preconditioning</kwd><kwd>Secondary Prevention</kwd><kwd>Stroke</kwd><kwd>Transient Ischemic Attack</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="sec1-1"><title><offsets xml_i="6434" xml_f="6435" txt_i="1551" txt_f="1552">I</offsets><sc><offsets xml_i="6439" xml_f="6450" txt_i="1552" txt_f="1563">NTRODUCTION</offsets></sc></title><p><offsets xml_i="6466" xml_f="6588" txt_i="1564" txt_f="1686">Stroke is the number one cause of death in China. The incidence rate of stroke was around 136–485 per 100,000 population.[</offsets><xref rid="ref1" ref-type="bibr"><offsets xml_i="6621" xml_f="6622" txt_i="1686" txt_f="1687">1</offsets></xref><offsets xml_i="6629" xml_f="6899" txt_i="1687" txt_f="1954">] Nondisabling cerebrovascular events consist of acute minor ischemic stroke (AMIS) and high-risk transient ischemic attack (TIA). The most commonly used definition of AMIS is a score of National Institutes of Health Stroke Scale (NIHSS) &lt;4 at the time of the event.[</offsets><xref rid="ref2" ref-type="bibr"><offsets xml_i="6932" xml_f="6933" txt_i="1954" txt_f="1955">2</offsets></xref><offsets xml_i="6940" xml_f="7153" txt_i="1955" txt_f="2168">] The combination of aspirin and clopidogrel within 24 h of an AMIS/TIA and continuation for 21 days was recommended according to the latest Chinese and American guidelines for the secondary prevention of stroke.[</offsets><xref rid="ref3" ref-type="bibr"><offsets xml_i="7186" xml_f="7187" txt_i="2168" txt_f="2169">3</offsets></xref><xref rid="ref4" ref-type="bibr"><offsets xml_i="7227" xml_f="7228" txt_i="2169" txt_f="2170">4</offsets></xref><offsets xml_i="7235" xml_f="7236" txt_i="2170" txt_f="2171">]</offsets></p><p><offsets xml_i="7243" xml_f="7461" txt_i="2172" txt_f="2390">In a large-scale clinical trial among patients with AMIS/TIA (the CHANCE study), the recurrence rates of stroke/TIA within 3 months were still as high as 9.4% even the patients received dual antiplatelets within 24 h.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="7494" xml_f="7495" txt_i="2390" txt_f="2391">5</offsets></xref><offsets xml_i="7502" xml_f="7719" txt_i="2391" txt_f="2608">] There are considerable proportional of patients who cannot arrive at the emergency rooms within 24 h to receive thrombolytic therapy or receive dual antiplatelet therapy on time in the real-world practice in China.[</offsets><xref rid="ref6" ref-type="bibr"><offsets xml_i="7752" xml_f="7753" txt_i="2608" txt_f="2609">6</offsets></xref><offsets xml_i="7760" xml_f="7900" txt_i="2609" txt_f="2749">] In addition, the published data demonstrating whether the guideline has changed the real-world clinical practice or not in China are rare.</offsets></p><p><offsets xml_i="7907" xml_f="8138" txt_i="2750" txt_f="2981">Remote ischemic conditioning (RIC) involves repetitive and brief inflation of a cuff around the limb to pressures above systolic blood pressure and deflation, in order to protect distant organs such as the heart, kidney, or brain.[</offsets><xref rid="ref7" ref-type="bibr"><offsets xml_i="8171" xml_f="8172" txt_i="2981" txt_f="2982">7</offsets></xref><offsets xml_i="8179" xml_f="8380" txt_i="2982" txt_f="3183">] Potential protective mechanisms involved in RIC include amelioration of oxidative damage, prevention of mitochondria-dependent cell death pathways, suppression of inflammation, and immune responses.[</offsets><xref rid="ref8" ref-type="bibr"><offsets xml_i="8413" xml_f="8414" txt_i="3183" txt_f="3184">8</offsets></xref><xref rid="ref9" ref-type="bibr"><offsets xml_i="8454" xml_f="8455" txt_i="3184" txt_f="3185">9</offsets></xref><offsets xml_i="8462" xml_f="8660" txt_i="3185" txt_f="3383">] Long-term regular (twice a day for at least 90 days) RIC showed protective effects in reducing stroke recurrence in symptomatic intracranial artery stenosis in small sample-size clinical studies.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="8694" xml_f="8696" txt_i="3383" txt_f="3385">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="8737" xml_f="8739" txt_i="3385" txt_f="3387">11</offsets></xref><offsets xml_i="8746" xml_f="8967" txt_i="3387" txt_f="3608">] However, the feasibility and safety of applying long-term regular RIC have not been systematically studied, and the prior study on investigating the protective effect of RIC to patients who suffered AMIS/TIA is limited.</offsets></p><p><offsets xml_i="8974" xml_f="9400" txt_i="3609" txt_f="4035">Considering all of the factors above, it is a logical step to design a single-arm study to assess the feasibility and safety of such intervention in this subgroup of stroke patients with AMIS/TIA before launching an expensive Phase II two-arm efficacy comparison study. We hypothesized that adjunctive twice-daily RIC for 3 months is feasible, safe, and can further reduce the cerebrovascular events in patients with AMIS/TIA.</offsets></p></sec><sec sec-type="methods" id="sec1-2"><title><offsets xml_i="9453" xml_f="9454" txt_i="4037" txt_f="4038">M</offsets><sc><offsets xml_i="9458" xml_f="9464" txt_i="4038" txt_f="4044">ETHODS</offsets></sc></title><sec id="sec2-1"><title><offsets xml_i="9501" xml_f="9517" txt_i="4045" txt_f="4061">Ethical approval</offsets></title><p><offsets xml_i="9528" xml_f="9980" txt_i="4062" txt_f="4514">The study is being conducted at four sites in China. The study protocol was approved by Institutional Review Board (IRB) at each study site. IRB meets regularly and monitors the progress of Preventing Ischemic Cerebrovascular events in high-risk patients with acute Non-disabling Ischemic Cerebrovascular events using RIC (PICNIC-One) study to ensure that research ethics are met and every participant receives the highest standard of human protection.</offsets></p></sec><sec id="sec2-2"><title><offsets xml_i="10014" xml_f="10026" txt_i="4516" txt_f="4528">Study design</offsets></title><p><offsets xml_i="10037" xml_f="10607" txt_i="4529" txt_f="5099">PICNIC-One is a single-arm, open-label, multicenter Phase IIa futility study. The antiplatelet strategy is based on physician's best judgment: aspirin alone, clopidogrel alone, or a combination of aspirin and clopidogrel. RIC is done by 5 cycles of 5-min inflation and 5-min deflation of bilateral upper-arm blood pressure cuffs to 200 mmHg twice daily for 90 days (45 min, twice a day). The primary objective is to explore the feasibility, safety, and preliminary efficacy of 3-month regular RIC in preventing recurrent ischemic stroke or TIA in patients with AMIS/TIA.</offsets></p></sec><sec id="sec2-3"><title><offsets xml_i="10641" xml_f="10659" txt_i="5101" txt_f="5119">Study organization</offsets></title><p><offsets xml_i="10670" xml_f="11535" txt_i="5120" txt_f="5985">PICNIC-One was designed by a team of researchers from Xuanwu Hospital, the Capital Medical University (China), and the Medical University of South Carolina (USA). It is being conducted at four sites in China: Xuanwu Hospital, Capital Medical University; Shengli Oilfield Center Hospital, the First Affiliated Hospital of Hainan Medical University, and Taoyuan People's Hospital. PICNIC-One Executive Committee includes project manager, research physicians/investigators, and clinical research coordinators. The project manager reviews case report forms to ensure that enrolment criteria were met, the protocol was correctly implemented, and reports were accurate each week after the intimation of enrolment. All investigators and study staffs were required to obtain certifications in NIHSS, Modified Rankin Scale (mRS), and Barthel Index through a secure website (</offsets><ext-link ext-link-type="uri" xlink:href="https://www.healthcarepoint.com"><offsets xml_i="11610" xml_f="11641" txt_i="5985" txt_f="6016">https://www.healthcarepoint.com</offsets></ext-link><offsets xml_i="11652" xml_f="11773" txt_i="6016" txt_f="6137">). In addition, they are required to attend a site training to understand the study protocol before initiating the study.</offsets></p></sec><sec id="sec2-4"><title><offsets xml_i="11807" xml_f="11819" txt_i="6139" txt_f="6151">Participants</offsets></title><p><offsets xml_i="11830" xml_f="11973" txt_i="6152" txt_f="6295">We planned to recruit adult (age ≥18 years old) patients of either gender who has AMIS/TIA with the following inclusion and exclusion criteria.</offsets></p><p><bold><offsets xml_i="11986" xml_f="12004" txt_i="6296" txt_f="6314">Inclusion criteria</offsets></bold></p><p><offsets xml_i="12018" xml_f="12465" txt_i="6315" txt_f="6762">Each participant must meet all the following criteria in order to participate in this study: (1) ≥18 years of any gender or ethnicity; (2) diagnosed with a noncardiogenic AMIS/TIA within 14 days of stroke symptoms' onset; AMIS is defined by NIHSS score ≤3 at the time of enrolment and TIA is defined as a transient episode of neurological dysfunction without acute infarction plus the moderate-to-high risk of stroke recurrence (defined as an ABCD</offsets><sup><offsets xml_i="12470" xml_f="12471" txt_i="6762" txt_f="6763">2</offsets></sup><offsets xml_i="12477" xml_f="12717" txt_i="6763" txt_f="7003"> [(a): age; (b): blood pressure; (c): clinical features of TIA; (d): diabetes and duration] score of ≥4 at the time of enrolment); (3) stable vital signs, normal cardiac (Class I–II in New York Heart Association Functional Classification),[</offsets><xref rid="ref12" ref-type="bibr"><offsets xml_i="12751" xml_f="12753" txt_i="7003" txt_f="7005">12</offsets></xref><offsets xml_i="12760" xml_f="13030" txt_i="7005" txt_f="7275">] hepatic (normal range in blood liver function tests) and renal functions (normal range in blood renal function tests); (4) able to consent by himself/herself or by a legally authorized representative; and (5) agreed to conduct regular RIC by himself/herself or others.</offsets></p><p><bold><offsets xml_i="13043" xml_f="13061" txt_i="7276" txt_f="7294">Exclusion criteria</offsets></bold></p><p><offsets xml_i="13075" xml_f="13825" txt_i="7295" txt_f="8039">Individuals who meet any of the following criteria will be excluded from the study: (1) diagnosis of brain hemorrhage or other pathologies, such as vascular malformation, tumor, abscess, or other nonvascular diseases, based on brain computed tomography (CT) or magnetic resonance imaging (MRI); (2) mRS score &gt;2 before the indexed event; (3) received intravenous thrombolytic therapy (alteplase or urokinase) or endovascular treatment for the indexed event; (4) contradiction to aspirin or clopidogrel (known allergy, severe asthma, or heart failure, etc.); (5) indication for anticoagulation therapy (cardiac source of embolus); (6) hemorrhagic tendency of any reason (including but not limited to hemostatic disorder, platelet count &lt;100 × 10</offsets><sup><offsets xml_i="13830" xml_f="13831" txt_i="8039" txt_f="8040">9</offsets></sup><offsets xml_i="13837" xml_f="13875" txt_i="8040" txt_f="8078">/L, a history of hepatic dysfunction, </offsets><italic><offsets xml_i="13883" xml_f="13886" txt_i="8078" txt_f="8081">etc</offsets></italic><offsets xml_i="13895" xml_f="14687" txt_i="8081" txt_f="8873">.); (7) any hemorrhagic transformation on brain scan (MRI or CT); (8) gastrointestinal bleed or major surgery within 3 months before the indexed event; (9) stroke or TIA due to medical procedure or other iatrogenic cause; (10) any upper extremity soft-tissue disease, vascular injury, or peripheral blood vessel disease which is contraindication for RIC; (11) hypertension with systolic blood pressure ≥200 mmHg despite medical treatment at the time of enrolment; (12) planned revascularization (any angioplasty or vascular surgery) within the next 3 months; (13) scheduled for surgery or intervention within the next 3 months that may affect the study procedure; (14) life expectancy ≤6 months; (15) pregnancy; and (16) currently receiving an investigational drug or device by other studies.</offsets></p></sec><sec id="sec2-5"><title><offsets xml_i="14721" xml_f="14752" txt_i="8875" txt_f="8906">Study procedures and treatments</offsets></title><p><offsets xml_i="14763" xml_f="14945" txt_i="8907" txt_f="9089">Potential participants will be identified from inpatient service or stroke emergency center. A research physician will confirm the diagnosis of AMIS (NIHSS score ≤3) or TIA with ABCD</offsets><sup><offsets xml_i="14950" xml_f="14951" txt_i="9089" txt_f="9090">2</offsets></sup><offsets xml_i="14957" xml_f="15645" txt_i="9090" txt_f="9778"> score ≥4. If the patient meets the criteria and gives a written informed consent, he/she will be instructed how to do RIC by himself/herself or family member. Patient will use an electric autocontrol device (patent number: ZL200820123637.X, China) for the procedure. RIC consists of five cycles of 5-min inflation at 200 mmHg and 5-min deflation of cuffs on bilateral upper limbs twice a day (45 min, twice a day). Medication strategy is based on physician's best judgment: aspirin alone (100 mg to 300 mg daily), clopidogrel alone (75 mg daily), or a combination of aspirin and clopidogrel. Study visits are scheduled on the day of enrolment (day 1), on day 30 ± 7, and on day 90 ± 14 [</offsets><xref ref-type="table" rid="T1"><offsets xml_i="15677" xml_f="15684" txt_i="9778" txt_f="9785">Table 1</offsets></xref><offsets xml_i="15691" xml_f="15693" txt_i="9785" txt_f="9787">].</offsets></p><table-wrap id="T1" position="float"><label><offsets xml_i="15741" xml_f="15748" txt_i="9788" txt_f="9795">Table 1</offsets></label><caption><p><offsets xml_i="15768" xml_f="15809" txt_i="9795" txt_f="9836">Event table of PICNIC-one study procedure</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" valign="top" colspan="1"><offsets xml_i="15925" xml_f="15930" txt_i="9837" txt_f="9842">Event</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="15978" xml_f="15987" txt_i="9842" txt_f="9851">Enrolment</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="16035" xml_f="16048" txt_i="9851" txt_f="9864">1-month visit</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="16096" xml_f="16109" txt_i="9864" txt_f="9877">3-month visit</offsets></th></tr><tr><th align="center" rowspan="1" colspan="1"><offsets xml_i="16166" xml_f="16171" txt_i="9877" txt_f="9882">Day 1</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="16219" xml_f="16229" txt_i="9882" txt_f="9892">Day 30 ± 7</offsets></th><th align="center" rowspan="1" colspan="1"><offsets xml_i="16277" xml_f="16288" txt_i="9892" txt_f="9903">Day 90 ± 14</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16358" xml_f="16374" txt_i="9903" txt_f="9919">Informed consent</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16422" xml_f="16423" txt_i="9920" txt_f="9921">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16471" xml_f="16472" txt_i="9922" txt_f="9923">O</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16520" xml_f="16521" txt_i="9924" txt_f="9925">O</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16576" xml_f="16596" txt_i="9926" txt_f="9946">Clinico-demographics</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16644" xml_f="16645" txt_i="9947" txt_f="9948">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16693" xml_f="16694" txt_i="9949" txt_f="9950">O</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16742" xml_f="16743" txt_i="9951" txt_f="9952">O</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="16798" xml_f="16809" txt_i="9953" txt_f="9964">Vital signs</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16857" xml_f="16858" txt_i="9965" txt_f="9966">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16906" xml_f="16907" txt_i="9967" txt_f="9968">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="16955" xml_f="16956" txt_i="9969" txt_f="9970">X</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17011" xml_f="17016" txt_i="9971" txt_f="9976">NIHSS</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17064" xml_f="17065" txt_i="9977" txt_f="9978">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17113" xml_f="17114" txt_i="9979" txt_f="9980">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17162" xml_f="17163" txt_i="9981" txt_f="9982">X</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17218" xml_f="17221" txt_i="9983" txt_f="9986">mRS</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17269" xml_f="17270" txt_i="9987" txt_f="9988">O</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17318" xml_f="17319" txt_i="9989" txt_f="9990">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17367" xml_f="17368" txt_i="9991" txt_f="9992">X</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17423" xml_f="17436" txt_i="9993" txt_f="10006">Barthel Index</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17484" xml_f="17485" txt_i="10007" txt_f="10008">O</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17533" xml_f="17534" txt_i="10009" txt_f="10010">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17582" xml_f="17583" txt_i="10011" txt_f="10012">X</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17638" xml_f="17646" txt_i="10013" txt_f="10021">Handgrip</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17694" xml_f="17695" txt_i="10022" txt_f="10023">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17743" xml_f="17744" txt_i="10024" txt_f="10025">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17792" xml_f="17793" txt_i="10026" txt_f="10027">X</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="17848" xml_f="17865" txt_i="10028" txt_f="10045">Biochemistry test</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17913" xml_f="17914" txt_i="10046" txt_f="10047">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="17962" xml_f="17965" txt_i="10048" txt_f="10051">(X)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18013" xml_f="18014" txt_i="10052" txt_f="10053">X</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18069" xml_f="18081" txt_i="10054" txt_f="10066">Brain MRI/CT</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18129" xml_f="18130" txt_i="10067" txt_f="10068">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18178" xml_f="18181" txt_i="10069" txt_f="10072">(X)</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18229" xml_f="18232" txt_i="10073" txt_f="10076">(X)</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18287" xml_f="18306" txt_i="10077" txt_f="10096">Outcome assessments</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18354" xml_f="18355" txt_i="10097" txt_f="10098">O</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18403" xml_f="18404" txt_i="10099" txt_f="10100">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18452" xml_f="18453" txt_i="10101" txt_f="10102">X</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18508" xml_f="18522" txt_i="10103" txt_f="10117">Adverse events</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18570" xml_f="18571" txt_i="10118" txt_f="10119">O</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18619" xml_f="18620" txt_i="10120" txt_f="10121">X</offsets></td><td align="center" rowspan="1" colspan="1"><offsets xml_i="18668" xml_f="18669" txt_i="10122" txt_f="10123">X</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="18719" xml_f="19195" txt_i="10124" txt_f="10600">PICNIC: Preventing Ischemic Cerebrovascular events in high-risk patients with acute Non-disabling Ischemic Cerebrovascular events using Remote Ischemic Conditioning; MRI: Magnetic resonance imaging; CT: Computed tomography; X: Scheduled procedure by the study protocol; (X): The procedure is not required by the study protocol, but would be needed if necessary; O: The procedure is not applicable; NIHSS: National Institutes of Health Stroke Scale; mRS: Modified Rankin Scale.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="sec2-6"><title><offsets xml_i="19265" xml_f="19279" txt_i="10602" txt_f="10616">Study outcomes</offsets></title><p><offsets xml_i="19290" xml_f="20088" txt_i="10617" txt_f="11412">The primary outcome is the number (percentage) of patients who have a recurrent ischemic stroke or TIA within 90 days after the indexed event. Ischemic stroke is defined as an acute focal infarction of the brain or retina with one of the following: (1) sudden onset of a new focal neurologic deficit lasting 24 h or more, with clinical or imaging evidence of infarction and not attributable to a nonischemic cause; or (2) a new focal neurologic deficit lasting for &lt;24 h but with neuroimaging evidence of new brain infarction and not attributable to a nonischemic cause; or (3) rapid worsening of an existing focal neurologic deficit and not attributable to a nonischemic cause, with evidence of new ischemic changes on MRI or CT of the brain and clearly distinct from the index ischemic event.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="20121" xml_f="20122" txt_i="11412" txt_f="11413">5</offsets></xref><offsets xml_i="20129" xml_f="20130" txt_i="11413" txt_f="11414">]</offsets></p><p><offsets xml_i="20137" xml_f="20982" txt_i="11415" txt_f="12257">Secondary outcome measures include: (1) The number (percentage) of patients who have a second ischemic stroke or TIA within 1 month after the indexed event; (2) the number (percentage) of patients with new cerebrovascular and coronary artery events within 1 and 3 months, which include hemorrhagic stroke, myocardial infarction, death from cardiovascular causes, and death from all causes, from the indexed event; (3) NIHSS score change (continuous) from the baseline to 1 and 3 months; (4) mRS score (continuous) and dichotomized at percentage with score ≤1 versus ≥2 at 1 and 3 months; (4) Barthel Index score (continuous) and dichotomized at percentage with score ≥95 versus &lt;95 at 1 and 3 months; and (5) handgrip strength change (continuous) on the affected side in patients with upper-limb motor deficit from baseline to 1 and 3 months.</offsets></p><p><offsets xml_i="20989" xml_f="21326" txt_i="12258" txt_f="12592">Compliance will be assessed with the simultaneous records, which are delivered by the electric autocontrol device through 4G signals. It will be used for feasibility assessment: the number (percentage) of patients who complete ≥50% and &lt;50% of the long-term regular 45-min complete RIC tasks as well as incomplete RIC tasks (≤45 min).</offsets></p><p><offsets xml_i="21333" xml_f="22216" txt_i="12593" txt_f="13476">Safety end points are risks of expected treatment-related local or systemic adverse events, including the number (percentage) of patients having pain with arms assessed by visual analog scale, redness or swelling of arms, skin petechiae on arms, palpitation, and dizziness. Any new condition (symptom, injury, or significant abnormal laboratory value) that is not present at the beginning of the study will be documented as an unexpected adverse event. Whether the unexpected adverse event is associated with the RIC device will be adjudicated by research physicians. Serious adverse events (SAEs) will be reported to the local IRB within 24 h. SAEs include death, life-threatening events, inpatient hospitalization or prolongation of existing hospitalization, requirements of medical/surgical intervention to prevent permanent impairment or damage, and other serious medical events.</offsets></p></sec><sec id="sec2-7"><title><offsets xml_i="22250" xml_f="22270" txt_i="13478" txt_f="13498">Statistical analysis</offsets></title><p><offsets xml_i="22281" xml_f="22434" txt_i="13499" txt_f="13652">The null hypothesis is that the recurrence rate of ischemic stroke/TIA within 3 months is greater than the largest regression probability of recurrence (</offsets><italic><offsets xml_i="22442" xml_f="22443" txt_i="13652" txt_f="13653">P</offsets></italic><sub><offsets xml_i="22457" xml_f="22458" txt_i="13653" txt_f="13654">0</offsets></sub><offsets xml_i="22464" xml_f="22625" txt_i="13654" txt_f="13815">); the alternative hypothesis is that the recurrence rate of ischemic stroke/TIA within 3 months is less than the smallest regression probability of recurrence (</offsets><italic><offsets xml_i="22633" xml_f="22634" txt_i="13815" txt_f="13816">P</offsets></italic><sub><offsets xml_i="22648" xml_f="22649" txt_i="13816" txt_f="13817">A</offsets></sub><offsets xml_i="22655" xml_f="22658" txt_i="13817" txt_f="13820">).[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="22692" xml_f="22694" txt_i="13820" txt_f="13822">13</offsets></xref><offsets xml_i="22701" xml_f="22702" txt_i="13822" txt_f="13823">]</offsets></p><p><offsets xml_i="22709" xml_f="22918" txt_i="13824" txt_f="14033">The CHANCE study is a large-scale (5170 patients) randomized controlled clinical trial investigating the superior medication strategy in secondary prevention in patients with AMIS/TIA in a Chinese population.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="22951" xml_f="22952" txt_i="14033" txt_f="14034">5</offsets></xref><offsets xml_i="22959" xml_f="23139" txt_i="14034" txt_f="14214">] In the CHANCE study, the recurrence rate of ischemic stroke/TIA within 3 months was 9.4% on the combination of clopidogrel and aspirin group and 13.2% on the aspirin-only group.[</offsets><xref rid="ref5" ref-type="bibr"><offsets xml_i="23172" xml_f="23173" txt_i="14214" txt_f="14215">5</offsets></xref><offsets xml_i="23180" xml_f="23270" txt_i="14215" txt_f="14305">] The recurrence rate after AMIS/TIA was around 10–20% according to epidemiology studies.[</offsets><xref rid="ref14" ref-type="bibr"><offsets xml_i="23304" xml_f="23306" txt_i="14305" txt_f="14307">14</offsets></xref><xref rid="ref15" ref-type="bibr"><offsets xml_i="23347" xml_f="23349" txt_i="14307" txt_f="14309">15</offsets></xref><xref rid="ref16" ref-type="bibr"><offsets xml_i="23390" xml_f="23392" txt_i="14309" txt_f="14311">16</offsets></xref><xref rid="ref17" ref-type="bibr"><offsets xml_i="23433" xml_f="23435" txt_i="14311" txt_f="14313">17</offsets></xref><xref rid="ref18" ref-type="bibr"><offsets xml_i="23476" xml_f="23478" txt_i="14313" txt_f="14315">18</offsets></xref><xref rid="ref19" ref-type="bibr"><offsets xml_i="23519" xml_f="23521" txt_i="14315" txt_f="14317">19</offsets></xref><offsets xml_i="23528" xml_f="23579" txt_i="14317" txt_f="14368">] With α as 0.95 and power as 0.80, we assume that </offsets><italic><offsets xml_i="23587" xml_f="23588" txt_i="14368" txt_f="14369">P</offsets></italic><sub><offsets xml_i="23602" xml_f="23603" txt_i="14369" txt_f="14370">0</offsets></sub><offsets xml_i="23609" xml_f="23619" txt_i="14370" txt_f="14380">= 12% and </offsets><italic><offsets xml_i="23627" xml_f="23628" txt_i="14380" txt_f="14381">P</offsets></italic><sub><offsets xml_i="23642" xml_f="23643" txt_i="14381" txt_f="14382">A</offsets></sub><offsets xml_i="23649" xml_f="23714" txt_i="14382" txt_f="14447">= 6% in the study, thus a minimally required sample size is 150 [</offsets><xref ref-type="fig" rid="F1"><offsets xml_i="23744" xml_f="23752" txt_i="14447" txt_f="14455">Figure 1</offsets></xref><offsets xml_i="23759" xml_f="23762" txt_i="14455" txt_f="14458">].[</offsets><xref rid="ref13" ref-type="bibr"><offsets xml_i="23796" xml_f="23798" txt_i="14458" txt_f="14460">13</offsets></xref><offsets xml_i="23805" xml_f="23904" txt_i="14460" txt_f="14559">] If the attrition rate can be kept at no higher than 10%, a sample size of 165 should be adequate.</offsets></p><fig id="F1" position="float"><label><offsets xml_i="23945" xml_f="23953" txt_i="14560" txt_f="14568">Figure 1</offsets></label><caption><p><offsets xml_i="23973" xml_f="24082" txt_i="14568" txt_f="14677">Sample size calculation according to one-sample single-stage procedure for the Phase II clinical trial. With </offsets><italic><offsets xml_i="24090" xml_f="24091" txt_i="14677" txt_f="14678">α</offsets></italic><offsets xml_i="24100" xml_f="24143" txt_i="14678" txt_f="14721"> as 0.95 and power as 0.80, we assume that </offsets><italic><offsets xml_i="24151" xml_f="24152" txt_i="14721" txt_f="14722">P</offsets></italic><sub><offsets xml_i="24166" xml_f="24167" txt_i="14722" txt_f="14723">0</offsets></sub><offsets xml_i="24173" xml_f="24185" txt_i="14723" txt_f="14735"> = 12%, and </offsets><italic><offsets xml_i="24193" xml_f="24194" txt_i="14735" txt_f="14736">P</offsets></italic><sub><offsets xml_i="24208" xml_f="24209" txt_i="14736" txt_f="14737">A</offsets></sub><offsets xml_i="24215" xml_f="24275" txt_i="14737" txt_f="14797"> = 6% in the study, a minimally required sample size is 150.</offsets></p></caption><graphic xlink:href="CMJ-131-347-g001"></graphic></fig><p><offsets xml_i="24347" xml_f="24695" txt_i="14798" txt_f="15146">Baseline categorical variables were listed as number (percentage). Baseline normally distributed continuous variables were reported as mean ± standard deviation (SD), while nonnormally distributed continuous variables were reported in median (interquartile range). The primary analysis is per-protocol analysis as this is an open, single-arm study.</offsets></p><p><offsets xml_i="24702" xml_f="25051" txt_i="15147" txt_f="15496">We use multivariate logistic regression models to assess the association between odds ratio of having recurrent ischemic stroke/TIA with compliance rate and other covariates. We also use repeated measures analysis with mixed models to analyze the changes in NIHSS score and handgrip strength between compliance rate and other covariates. A value of </offsets><italic><offsets xml_i="25059" xml_f="25060" txt_i="15496" txt_f="15497">P</offsets></italic><offsets xml_i="25069" xml_f="25121" txt_i="15497" txt_f="15546"> &lt; 0.05 was considered statistically significant.</offsets></p></sec></sec><sec sec-type="discussion" id="sec1-3"><title><offsets xml_i="25183" xml_f="25184" txt_i="15549" txt_f="15550">D</offsets><sc><offsets xml_i="25188" xml_f="25197" txt_i="15550" txt_f="15559">ISCUSSION</offsets></sc></title><p><offsets xml_i="25213" xml_f="25641" txt_i="15560" txt_f="15988">PICNIC-One study is a single-arm Phase IIa futility study aiming to investigate the feasibility, safety, and preliminary efficacy of regular long-term RIC in preventing recurrent stroke and other vascular events in patients with AMIS/TIA. The study will provide evidence whether or not to initiate a large-scale and multicenter randomized controlled clinical study or to avoid futile, expensive, and unnecessary Phase II trials.</offsets></p><p><offsets xml_i="25648" xml_f="26256" txt_i="15989" txt_f="16597">PICNIC-One is expected to make several unique contributions in understanding the potential role of RIC in secondary stroke prevention. First, PICNIC-One will provide preliminary evidence of the efficacy of RIC as an adjunctive therapy to pharmacotherapy after an AMIS/TIA in the real-world practice. Second, PICNIC-One will advance the current knowledge of feasibility of applying long-term regular RIC in this subset of stroke population. To our knowledge, only several small clinical trials investigated the long-term regular RIC in stroke patients, and three of them were carried at the same single site.[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="26290" xml_f="26292" txt_i="16597" txt_f="16599">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="26333" xml_f="26335" txt_i="16599" txt_f="16601">11</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="26376" xml_f="26378" txt_i="16601" txt_f="16603">20</offsets></xref><offsets xml_i="26385" xml_f="27221" txt_i="16603" txt_f="17439">] It remains a concern whether patients could strictly follow the study protocol to use RIC twice daily (90 min daily) for 90 days. The feasibility of applying RIC in multiple sites is also uncertain and requires a careful feasibility assessment. The study has four sites in different regions of China: two of them are academic tertiary hospitals and the other two are nonacademic community hospitals. The electric autocontrol RIC device used in this study has the capacity to upload application data simultaneously through 4G signals to allow the study team to track the compliance rate. Third, PICNIC-One is expected to provide evidence of the safety of RIC. Adverse events related to RIC were not sufficiently assessed due to inadequate sample size. Although there have been no reports of RIC-related SAEs in prior clinical studies,[</offsets><xref rid="ref10" ref-type="bibr"><offsets xml_i="27255" xml_f="27257" txt_i="17439" txt_f="17441">10</offsets></xref><xref rid="ref11" ref-type="bibr"><offsets xml_i="27298" xml_f="27300" txt_i="17441" txt_f="17443">11</offsets></xref><xref rid="ref20" ref-type="bibr"><offsets xml_i="27341" xml_f="27343" txt_i="17443" txt_f="17445">20</offsets></xref><xref rid="ref21" ref-type="bibr"><offsets xml_i="27384" xml_f="27386" txt_i="17445" txt_f="17447">21</offsets></xref><xref rid="ref22" ref-type="bibr"><offsets xml_i="27427" xml_f="27429" txt_i="17447" txt_f="17449">22</offsets></xref><xref rid="ref23" ref-type="bibr"><offsets xml_i="27470" xml_f="27472" txt_i="17449" txt_f="17451">23</offsets></xref><xref rid="ref24" ref-type="bibr"><offsets xml_i="27513" xml_f="27515" txt_i="17451" txt_f="17453">24</offsets></xref><xref rid="ref25" ref-type="bibr"><offsets xml_i="27556" xml_f="27558" txt_i="17453" txt_f="17455">25</offsets></xref><xref rid="ref26" ref-type="bibr"><offsets xml_i="27599" xml_f="27601" txt_i="17455" txt_f="17457">26</offsets></xref><xref rid="ref27" ref-type="bibr"><offsets xml_i="27642" xml_f="27644" txt_i="17457" txt_f="17459">27</offsets></xref><xref rid="ref28" ref-type="bibr"><offsets xml_i="27685" xml_f="27687" txt_i="17459" txt_f="17461">28</offsets></xref><xref rid="ref29" ref-type="bibr"><offsets xml_i="27728" xml_f="27730" txt_i="17461" txt_f="17463">29</offsets></xref><xref rid="ref30" ref-type="bibr"><offsets xml_i="27771" xml_f="27773" txt_i="17463" txt_f="17465">30</offsets></xref><xref rid="ref31" ref-type="bibr"><offsets xml_i="27814" xml_f="27816" txt_i="17465" txt_f="17467">31</offsets></xref><xref rid="ref32" ref-type="bibr"><offsets xml_i="27857" xml_f="27859" txt_i="17467" txt_f="17469">32</offsets></xref><xref rid="ref33" ref-type="bibr"><offsets xml_i="27900" xml_f="27902" txt_i="17469" txt_f="17471">33</offsets></xref><xref rid="ref34" ref-type="bibr"><offsets xml_i="27943" xml_f="27945" txt_i="17471" txt_f="17473">34</offsets></xref><xref rid="ref35" ref-type="bibr"><offsets xml_i="27986" xml_f="27988" txt_i="17473" txt_f="17475">35</offsets></xref><xref rid="ref36" ref-type="bibr"><offsets xml_i="28029" xml_f="28031" txt_i="17475" txt_f="17477">36</offsets></xref><offsets xml_i="28038" xml_f="28236" txt_i="17477" txt_f="17675">] SAEs may occur at a low rate and may be only detected with large sample size and many studies. PICNIC-One will continue to monitor the safety of long-term regular RIC in patients with an AMIS/TIA.</offsets></p><p><offsets xml_i="28243" xml_f="28537" txt_i="17676" txt_f="17970">In summary, we designed PICNIC-One as a single-arm study without a control group because it is an early-phase futility study without prior preliminary data. The goal was to gain critical knowledge about the feasibility and safety of the long-term daily RIC in these stroke patients' population.</offsets></p><sec id="sec2-8"><title><offsets xml_i="28565" xml_f="28598" txt_i="17971" txt_f="18004">Financial support and sponsorship</offsets></title><p><offsets xml_i="28609" xml_f="28921" txt_i="18005" txt_f="18317">PICNIC-One study is supported by the grants from the National Natural Science Foundation of China (No. 81325007 and No. 81620108011), the Capital Health Research and Special Development (No. 2016-4-1032), the American Stroke Association (No. 14SDG1829003), and the National Institute of Health (No. P20GM109040).</offsets></p></sec><sec id="sec2-9" sec-type="COI-statement"><title><offsets xml_i="28980" xml_f="29001" txt_i="18319" txt_f="18340">Conflicts of interest</offsets></title><p><offsets xml_i="29012" xml_f="29047" txt_i="18341" txt_f="18376">There are no conflicts of interest.</offsets></p></sec></sec></body><back><ack><title>Acknowledgment</title><p>We acknowledge Dr. Alexander Paroshos for English language edit.</p></ack><fn-group><fn fn-type="edited-by"><p><bold>Edited by:</bold> Ning-Ning Wang</p></fn></fn-group><ref-list><title>R<sc>EFERENCES</sc></title><ref id="ref1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wong</surname><given-names>KS</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Stroke and stroke care in China: Huge burden, significant workload, and a national priority</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>3651</fpage><lpage>4</lpage><comment>doi: 10.1161/strokeaha.111.635755</comment><pub-id pub-id-type="pmid">22052510</pub-id></element-citation></ref><ref id="ref2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>U</given-names></name><name><surname>Baumgartner</surname><given-names>A</given-names></name><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Nedeltchev</surname><given-names>K</given-names></name><name><surname>Gralla</surname><given-names>J</given-names></name><name><surname>De Marchis</surname><given-names>GM</given-names></name><etal></etal></person-group><article-title>What is a minor stroke?</article-title><source>Stroke</source><year>2010</year><volume>41</volume><fpage>661</fpage><lpage>6</lpage><comment>doi: 10.1161/strokeaha.109.572883</comment><pub-id pub-id-type="pmid">20185781</pub-id></element-citation></ref><ref id="ref3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kernan</surname><given-names>WN</given-names></name><name><surname>Ovbiagele</surname><given-names>B</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Bravata</surname><given-names>DM</given-names></name><name><surname>Chimowitz</surname><given-names>MI</given-names></name><name><surname>Ezekowitz</surname><given-names>MD</given-names></name><etal></etal></person-group><article-title>Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>2160</fpage><lpage>236</lpage><comment>doi: 10.1161/str.0000000000000024</comment><pub-id pub-id-type="pmid">24788967</pub-id></element-citation></ref><ref id="ref4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu M and Pu</surname><given-names>C</given-names></name></person-group><article-title>2014 chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack</article-title><source>International journal of stroke: Official journal of the International Stroke Society</source><year>2017</year><volume>12</volume><fpage>302</fpage><lpage>20</lpage><comment>doi: 10.1177/1747493017694391</comment><pub-id pub-id-type="pmid">28381199</pub-id></element-citation></ref><ref id="ref5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Clopidogrel with aspirin in acute minor stroke or transient ischemic attack</article-title><source>New Engl J Med</source><year>2013</year><volume>369</volume><fpage>11</fpage><lpage>9</lpage><comment>doi: 10.1056/NEJMoa1215340</comment><pub-id pub-id-type="pmid">23803136</pub-id></element-citation></ref><ref id="ref6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H</given-names></name><name><surname>Zhu</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>JW</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Factors associated with prehospital delays in the presentation of acute stroke in urban China</article-title><source>Stroke</source><year>2012</year><volume>43</volume><fpage>362</fpage><lpage>70</lpage><comment>doi: 10.1161/strokeaha.111.623512</comment><pub-id pub-id-type="pmid">22246693</pub-id></element-citation></ref><ref id="ref7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hess</surname><given-names>DC</given-names></name><name><surname>Blauenfeldt</surname><given-names>RA</given-names></name><name><surname>Andersen</surname><given-names>G</given-names></name><name><surname>Hougaard</surname><given-names>KD</given-names></name><name><surname>Hoda</surname><given-names>MN</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><etal></etal></person-group><article-title>Remote ischaemic conditioning-a new paradigm of self-protection in the brain</article-title><source>Nat Rev Neurol</source><year>2015</year><volume>11</volume><fpage>698</fpage><lpage>710</lpage><comment>doi: 10.1038/nrneurol.2015.223</comment><pub-id pub-id-type="pmid">26585977</pub-id></element-citation></ref><ref id="ref8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narayanan</surname><given-names>SV</given-names></name><name><surname>Dave</surname><given-names>KR</given-names></name><name><surname>Perez-Pinzon</surname><given-names>MA</given-names></name></person-group><article-title>Ischemic preconditioning and clinical scenarios</article-title><source>Curr Opin Neurol</source><year>2013</year><volume>26</volume><fpage>1</fpage><lpage>7</lpage><comment>doi: 10.1097/WCO.0b013e32835bf200</comment><pub-id pub-id-type="pmid">23197083</pub-id></element-citation></ref><ref id="ref9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stenzel-Poore</surname><given-names>MP</given-names></name><name><surname>Stevens</surname><given-names>SL</given-names></name><name><surname>Xiong</surname><given-names>Z</given-names></name><name><surname>Lessov</surname><given-names>NS</given-names></name><name><surname>Harrington</surname><given-names>CA</given-names></name><name><surname>Mori</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: Similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states</article-title><source>Lancet</source><year>2003</year><volume>362</volume><fpage>1028</fpage><lpage>37</lpage><comment>doi: 10.1016/s0140-6736(03)14412-1</comment><pub-id pub-id-type="pmid">14522533</pub-id></element-citation></ref><ref id="ref10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>R</given-names></name><name><surname>Asmaro</surname><given-names>K</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Xi</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis</article-title><source>Neurology</source><year>2012</year><volume>79</volume><fpage>1853</fpage><lpage>61</lpage><comment>doi: 10.1212/WNL.0b013e318271f76a</comment><pub-id pub-id-type="pmid">23035060</pub-id></element-citation></ref><ref id="ref11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>R</given-names></name><name><surname>Ding</surname><given-names>Y</given-names></name><name><surname>Asmaro</surname><given-names>K</given-names></name><name><surname>Brogan</surname><given-names>D</given-names></name><name><surname>Meng</surname><given-names>L</given-names></name><name><surname>Sui</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Ischemic conditioning is safe and effective for Octo- and nonagenarians in stroke prevention and treatment</article-title><source>Neurotherapeutics</source><year>2015</year><volume>12</volume><fpage>667</fpage><lpage>77</lpage><comment>doi: 10.1007/s13311-015-0358-6</comment><pub-id pub-id-type="pmid">25956401</pub-id></element-citation></ref><ref id="ref12"><label>12</label><element-citation publication-type="book"><article-title>The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels</article-title><year>1994</year><edition>9th ed</edition><publisher-loc>Boston, Mass</publisher-loc><publisher-name>Little, Brown and Co</publisher-name></element-citation></ref><ref id="ref13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fleming</surname><given-names>TR</given-names></name></person-group><article-title>One-sample multiple testing procedure for phase II clinical trials</article-title><source>Biometrics</source><year>1982</year><volume>38</volume><fpage>143</fpage><lpage>51</lpage><comment>doi: 10.2307/2530297</comment><pub-id pub-id-type="pmid">7082756</pub-id></element-citation></ref><ref id="ref14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><etal></etal></person-group><article-title>Factors for short-term outcomes in patients with a minor stroke: Results from china national stroke registry</article-title><source>BMC Neurol</source><year>2015</year><volume>15</volume><fpage>253</fpage><comment>doi: 10.1186/s12883-015-0505-z</comment><pub-id pub-id-type="pmid">26645312</pub-id></element-citation></ref><ref id="ref15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SC</given-names></name><name><surname>Gress</surname><given-names>DR</given-names></name><name><surname>Browner</surname><given-names>WS</given-names></name><name><surname>Sidney</surname><given-names>S</given-names></name></person-group><article-title>Short-term prognosis after emergency department diagnosis of TIA</article-title><source>JAMA</source><year>2000</year><volume>284</volume><fpage>2901</fpage><lpage>6</lpage><comment>doi: 10.1001/jama.284.22.2901</comment><pub-id pub-id-type="pmid">11147987</pub-id></element-citation></ref><ref id="ref16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coull</surname><given-names>AJ</given-names></name><name><surname>Lovett</surname><given-names>JK</given-names></name><name><surname>Rothwell</surname><given-names>PM</given-names></name><name><surname>Oxford Vascular</surname><given-names>Study</given-names></name></person-group><article-title>Population based study of early risk of stroke after transient ischaemic attack or minor stroke: Implications for public education and organisation of services</article-title><source>BMJ</source><year>2004</year><volume>328</volume><fpage>326</fpage><comment>doi: 10.1136/bmj.37991.635266.44</comment><pub-id pub-id-type="pmid">14744823</pub-id></element-citation></ref><ref id="ref17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>MD</given-names></name><name><surname>Yiannakoulias</surname><given-names>N</given-names></name><name><surname>Jeerakathil</surname><given-names>T</given-names></name><name><surname>Tu</surname><given-names>JV</given-names></name><name><surname>Svenson</surname><given-names>LW</given-names></name><name><surname>Schopflocher</surname><given-names>DP</given-names></name><etal></etal></person-group><article-title>The high risk of stroke immediately after transient ischemic attack: A population-based study</article-title><source>Neurology</source><year>2004</year><volume>62</volume><fpage>2015</fpage><lpage>20</lpage><comment>doi: 10.1212/01.WNL.0000129482.70315.2F</comment><pub-id pub-id-type="pmid">15184607</pub-id></element-citation></ref><ref id="ref18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kleindorfer</surname><given-names>D</given-names></name><name><surname>Panagos</surname><given-names>P</given-names></name><name><surname>Pancioli</surname><given-names>A</given-names></name><name><surname>Khoury</surname><given-names>J</given-names></name><name><surname>Kissela</surname><given-names>B</given-names></name><name><surname>Woo</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Incidence and short-term prognosis of transient ischemic attack in a population-based study</article-title><source>Stroke</source><year>2005</year><volume>36</volume><fpage>720</fpage><lpage>3</lpage><comment>doi: 10.1161/01.STR.0000158917.59233.b7</comment><pub-id pub-id-type="pmid">15731465</pub-id></element-citation></ref><ref id="ref19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ois</surname><given-names>A</given-names></name><name><surname>Gomis</surname><given-names>M</given-names></name><name><surname>Rodríguez-Campello</surname><given-names>A</given-names></name><name><surname>Cuadrado-Godia</surname><given-names>E</given-names></name><name><surname>Jiménez-Conde</surname><given-names>J</given-names></name><name><surname>Pont-Sunyer</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke</article-title><source>Stroke</source><year>2008</year><volume>39</volume><fpage>1717</fpage><lpage>21</lpage><comment>doi: 10.1161/strokeaha.107.505438</comment><pub-id pub-id-type="pmid">18369168</pub-id></element-citation></ref><ref id="ref20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Meng</surname><given-names>R</given-names></name><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Hou</surname><given-names>B</given-names></name><name><surname>Jiao</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Safety and efficacy of remote ischemic preconditioning in patients with severe carotid artery stenosis before carotid artery stenting: A Proof-of-concept, randomized controlled trial</article-title><source>Circulation</source><year>2017</year><volume>135</volume><fpage>1325</fpage><lpage>35</lpage><comment>doi: 10.1161/circulationaha.116.024807</comment><pub-id pub-id-type="pmid">28174194</pub-id></element-citation></ref><ref id="ref21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munk</surname><given-names>K</given-names></name><name><surname>Andersen</surname><given-names>NH</given-names></name><name><surname>Schmidt</surname><given-names>MR</given-names></name><name><surname>Nielsen</surname><given-names>SS</given-names></name><name><surname>Terkelsen</surname><given-names>CJ</given-names></name><name><surname>Sloth</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Remote ischemic conditioning in patients with myocardial infarction treated with primary angioplasty: Impact on left ventricular function assessed by comprehensive echocardiography and gated single-photon emission CT</article-title><source>Circ Cardiovasc Imaging</source><year>2010</year><volume>3</volume><fpage>656</fpage><lpage>62</lpage><comment>doi: 10.1161/circimaging.110.957340</comment><pub-id pub-id-type="pmid">20826592</pub-id></element-citation></ref><ref id="ref22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crimi</surname><given-names>G</given-names></name><name><surname>Pica</surname><given-names>S</given-names></name><name><surname>Raineri</surname><given-names>C</given-names></name><name><surname>Bramucci</surname><given-names>E</given-names></name><name><surname>De Ferrari</surname><given-names>GM</given-names></name><name><surname>Klersy</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: A randomized controlled trial</article-title><source>JACC Cardiovasc Interv</source><year>2013</year><volume>6</volume><fpage>1055</fpage><lpage>63</lpage><comment>doi: 10.1016/j.jcin.2013.05.011</comment><pub-id pub-id-type="pmid">24156966</pub-id></element-citation></ref><ref id="ref23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>White</surname><given-names>SK</given-names></name><name><surname>Frohlich</surname><given-names>GM</given-names></name><name><surname>Sado</surname><given-names>DM</given-names></name><name><surname>Maestrini</surname><given-names>V</given-names></name><name><surname>Fontana</surname><given-names>M</given-names></name><name><surname>Treibel</surname><given-names>TA</given-names></name><etal></etal></person-group><article-title>Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction</article-title><source>JACC Cardiovasc Interv</source><year>2015</year><volume>8</volume><fpage>178</fpage><lpage>88</lpage><comment>doi: 10.1016/j.jcin.2014.05.015</comment><pub-id pub-id-type="pmid">25240548</pub-id></element-citation></ref><ref id="ref24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>R</given-names></name><name><surname>Piler</surname><given-names>P</given-names></name><name><surname>Bedanova</surname><given-names>H</given-names></name><name><surname>Adamek</surname><given-names>P</given-names></name><name><surname>Grodecka</surname><given-names>L</given-names></name><name><surname>Freiberger</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Myocardial injury is decreased by late remote ischaemic preconditioning and aggravated by tramadol in patients undergoing cardiac surgery: A randomised controlled trial</article-title><source>Interact Cardiovasc Thorac Surg</source><year>2010</year><volume>11</volume><fpage>758</fpage><lpage>62</lpage><comment>doi: 10.1510/icvts.2010.243600</comment><pub-id pub-id-type="pmid">20847065</pub-id></element-citation></ref><ref id="ref25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>Remote perconditioning reduces myocardial injury in adult valve replacement: A randomized controlled trial</article-title><source>J Surg Res</source><year>2010</year><volume>164</volume><fpage>e21</fpage><lpage>6</lpage><comment>doi: 10.1016/j.jss.2010.06.016</comment><pub-id pub-id-type="pmid">20850778</pub-id></element-citation></ref><ref id="ref26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>YS</given-names></name><name><surname>Shim</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>JC</given-names></name><name><surname>Kang</surname><given-names>KS</given-names></name><name><surname>Seo</surname><given-names>YH</given-names></name><name><surname>Ahn</surname><given-names>KR</given-names></name><etal></etal></person-group><article-title>Effect of remote ischemic preconditioning on renal dysfunction after complex valvular heart surgery: A randomized controlled trial</article-title><source>J Thorac Cardiovasc Surg</source><year>2011</year><volume>142</volume><fpage>148</fpage><lpage>54</lpage><comment>doi: 10.1016/j.jtcvs.2010.11.018</comment><pub-id pub-id-type="pmid">21272897</pub-id></element-citation></ref><ref id="ref27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>S</given-names></name><name><surname>Katsnelson</surname><given-names>M</given-names></name><name><surname>Dong</surname><given-names>C</given-names></name><name><surname>Perez-Pinzon</surname><given-names>M</given-names></name></person-group><article-title>Remote ischemic limb preconditioning after subarachnoid hemorrhage: A phase ib study of safety and feasibility</article-title><source>Stroke</source><year>2011</year><volume>42</volume><fpage>1387</fpage><lpage>91</lpage><comment>doi: 10.1161/STROKEAHA.110.605840</comment><pub-id pub-id-type="pmid">21415404</pub-id></element-citation></ref><ref id="ref28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bøtker</surname><given-names>HE</given-names></name><name><surname>Kharbanda</surname><given-names>R</given-names></name><name><surname>Schmidt</surname><given-names>MR</given-names></name><name><surname>Bøttcher</surname><given-names>M</given-names></name><name><surname>Kaltoft</surname><given-names>AK</given-names></name><name><surname>Terkelsen</surname><given-names>CJ</given-names></name><etal></etal></person-group><article-title>Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect on myocardial salvage in patients with acute myocardial infarction: A randomised trial</article-title><source>Lancet</source><year>2010</year><volume>375</volume><fpage>727</fpage><lpage>34</lpage><comment>doi: 10.1016/s0140-6736(09)62001-8</comment><pub-id pub-id-type="pmid">20189026</pub-id></element-citation></ref><ref id="ref29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rentoukas</surname><given-names>I</given-names></name><name><surname>Giannopoulos</surname><given-names>G</given-names></name><name><surname>Kaoukis</surname><given-names>A</given-names></name><name><surname>Kossyvakis</surname><given-names>C</given-names></name><name><surname>Raisakis</surname><given-names>K</given-names></name><name><surname>Driva</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Cardioprotective role of remote ischemic periconditioning in primary percutaneous coronary intervention: Enhancement by opioid action</article-title><source>JACC Cardiovasc Interv</source><year>2010</year><volume>3</volume><fpage>49</fpage><lpage>55</lpage><comment>doi: 10.1016/j.jcin.2009.10.015</comment><pub-id pub-id-type="pmid">20129568</pub-id></element-citation></ref><ref id="ref30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prunier</surname><given-names>F</given-names></name><name><surname>Angoulvant</surname><given-names>D</given-names></name><name><surname>Saint Etienne</surname><given-names>C</given-names></name><name><surname>Vermes</surname><given-names>E</given-names></name><name><surname>Gilard</surname><given-names>M</given-names></name><name><surname>Piot</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>The RIPOST-MI study, assessing remote ischemic perconditioning alone or in combination with local ischemic postconditioning in ST-segment elevation myocardial infarction</article-title><source>Basic Res Cardiol</source><year>2014</year><volume>109</volume><fpage>400</fpage><comment>doi: 10.1007/s00395-013-0400-y</comment><pub-id pub-id-type="pmid">24407359</pub-id></element-citation></ref><ref id="ref31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manchurov</surname><given-names>V</given-names></name><name><surname>Ryazankina</surname><given-names>N</given-names></name><name><surname>Khmara</surname><given-names>T</given-names></name><name><surname>Skrypnik</surname><given-names>D</given-names></name><name><surname>Reztsov</surname><given-names>R</given-names></name><name><surname>Vasilieva</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Remote ischemic preconditioning and endothelial function in patients with acute myocardial infarction and primary PCI</article-title><source>Am J Med</source><year>2014</year><volume>127</volume><fpage>670</fpage><lpage>3</lpage><comment>doi: 10.1016/j.amjmed.2014.02.012</comment><pub-id pub-id-type="pmid">24565591</pub-id></element-citation></ref><ref id="ref32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sloth</surname><given-names>AD</given-names></name><name><surname>Schmidt</surname><given-names>MR</given-names></name><name><surname>Munk</surname><given-names>K</given-names></name><name><surname>Kharbanda</surname><given-names>RK</given-names></name><name><surname>Redington</surname><given-names>AN</given-names></name><name><surname>Schmidt</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Improved long-term clinical outcomes in patients with ST-elevation myocardial infarction undergoing remote ischaemic conditioning as an adjunct to primary percutaneous coronary intervention</article-title><source>Eur Heart J</source><year>2014</year><volume>35</volume><fpage>168</fpage><lpage>75</lpage><comment>doi: 10.1093/eurheartj/eht369</comment><pub-id pub-id-type="pmid">24031025</pub-id></element-citation></ref><ref id="ref33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hougaard</surname><given-names>KD</given-names></name><name><surname>Hjort</surname><given-names>N</given-names></name><name><surname>Zeidler</surname><given-names>D</given-names></name><name><surname>Sørensen</surname><given-names>L</given-names></name><name><surname>Nørgaard</surname><given-names>A</given-names></name><name><surname>Hansen</surname><given-names>TM</given-names></name><etal></etal></person-group><article-title>Remote ischemic perconditioning as an adjunct therapy to thrombolysis in patients with acute ischemic stroke: A randomized trial</article-title><source>Stroke</source><year>2014</year><volume>45</volume><fpage>159</fpage><lpage>67</lpage><comment>doi: 10.1161/strokeaha.113.001346</comment><pub-id pub-id-type="pmid">24203849</pub-id></element-citation></ref><ref id="ref34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venugopal</surname><given-names>V</given-names></name><name><surname>Hausenloy</surname><given-names>DJ</given-names></name><name><surname>Ludman</surname><given-names>A</given-names></name><name><surname>Di Salvo</surname><given-names>C</given-names></name><name><surname>Kolvekar</surname><given-names>S</given-names></name><name><surname>Yap</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>Remote ischaemic preconditioning reduces myocardial injury in patients undergoing cardiac surgery with cold-blood cardioplegia: A randomised controlled trial</article-title><source>Heart</source><year>2009</year><volume>95</volume><fpage>1567</fpage><lpage>71</lpage><comment>doi: 10.1136/hrt.2008.155770</comment><pub-id pub-id-type="pmid">19508973</pub-id></element-citation></ref><ref id="ref35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>N</given-names></name><name><surname>Rizwi</surname><given-names>F</given-names></name><name><surname>Iqbal</surname><given-names>A</given-names></name><name><surname>Rashid</surname><given-names>A</given-names></name></person-group><article-title>Induced remote ischemic pre-conditioning on ischemia-reperfusion injury in patients undergoing coronary artery bypass</article-title><source>J Coll Physicians Surg Pak</source><year>2010</year><volume>20</volume><fpage>427</fpage><lpage>31</lpage><comment>doi: 07.2010/jcpsp.427431</comment><pub-id pub-id-type="pmid">20642939</pub-id></element-citation></ref><ref id="ref36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>IA</given-names></name><name><surname>Mascaro</surname><given-names>JG</given-names></name><name><surname>Steeds</surname><given-names>RP</given-names></name><name><surname>Frenneaux</surname><given-names>MP</given-names></name><name><surname>Nightingale</surname><given-names>P</given-names></name><name><surname>Gosling</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Remote ischemic preconditioning in human coronary artery bypass surgery: From promise to disappointment?</article-title><source>Circulation</source><year>2010</year><volume>122</volume><fpage>S53</fpage><lpage>9</lpage><comment>doi: 10.1161/circulationaha.109.926667</comment><pub-id pub-id-type="pmid">20837926</pub-id></element-citation></ref></ref-list></back></article>